Investors Alert: Class Action Filed Against Pacira Biosciences Over Securities Fraud
On February 11, 2025, Pomerantz LLP issued a notification indicating the initiation of a class action lawsuit against Pacira Biosciences, Inc. (NASDAQ: PCRX). This lawsuit targets investors who suffered losses during the period in which alleged improper conduct and securities fraud occurred.
If you purchased shares of Pacira or otherwise obtained its securities during the class period, this information is particularly relevant for you as the firm has set a deadline of March 14, 2025, for investors to request to be named as Lead Plaintiff in the ongoing litigation. Individuals interested in pursuing this opportunity should contact Danielle Peyton at Pomerantz LLP via email at dp@pomerantzlaw.com or by phone at 646-581-9980.
This class action arises from claims that Pacira and certain of its officers and directors engaged in illegal business activities, potentially misleading shareholders concerning the viability and valuation of Pacira’s products.
The catalyst for this action was Pacira's announcement on August 9, 2024, regarding the U.S. District Court's ruling that invalidated its '495 patent, which covers Exparel, a non-opioid treatment for pain management. The court's decision was based on findings of obviousness and anticipation, which culminated in a drastic share price decline. Following the announcement, Pacira's stock plummeted by $10.66, a staggering 47.67%, leaving shares to close at $11.70.
This steep drop signals the potential financial implications for investors and heightens the urgency surrounding the class action lawsuit. Pomerantz LLP, known for its expertise in corporate and securities litigation, emphasizes the importance of protecting investors from such detrimental financial impacts stemming from alleged misconduct.
Founded by Abraham L. Pomerantz, who is regarded as a pioneer in the field of class-action securities litigation, the firm has dedicated over eight decades to advocating for victims of securities fraud and misconduct. They’ve successfully recovered numerous multi-million dollar settlements for their clients, illustrating their commitment to holding corporations accountable.
For those looking to navigate these tumultuous waters of investment and litigation, the resources provided through Pomerantz LLP allow affected investors to make informed decisions about their next steps. By participating in this class action, investors may seek remediation for the losses they incurred as a result of the alleged malfeasance of Pacira’s leadership.
Investors are reminded that the deadline to become involved is fast approaching. It is pertinent to act swiftly to secure your place in this potentially significant case. By coming together, affected investors can amplify their influence in the quest for justice and recovery. Visit www.pomerantzlaw.com for additional details and to review the filed complaint.
In conclusion, with rising concerns surrounding corporate governance and transparency, cases like that of Pacira Biosciences spotlight the critical nature of investor vigilance in the face of potentially deceptive practices. It’s essential for shareholders to stay informed and proactive regarding their rights and the avenues available for pursuing compensation, especially during times of such significant corporate distress.
If you purchased shares of Pacira or otherwise obtained its securities during the class period, this information is particularly relevant for you as the firm has set a deadline of March 14, 2025, for investors to request to be named as Lead Plaintiff in the ongoing litigation. Individuals interested in pursuing this opportunity should contact Danielle Peyton at Pomerantz LLP via email at dp@pomerantzlaw.com or by phone at 646-581-9980.
This class action arises from claims that Pacira and certain of its officers and directors engaged in illegal business activities, potentially misleading shareholders concerning the viability and valuation of Pacira’s products.
The catalyst for this action was Pacira's announcement on August 9, 2024, regarding the U.S. District Court's ruling that invalidated its '495 patent, which covers Exparel, a non-opioid treatment for pain management. The court's decision was based on findings of obviousness and anticipation, which culminated in a drastic share price decline. Following the announcement, Pacira's stock plummeted by $10.66, a staggering 47.67%, leaving shares to close at $11.70.
This steep drop signals the potential financial implications for investors and heightens the urgency surrounding the class action lawsuit. Pomerantz LLP, known for its expertise in corporate and securities litigation, emphasizes the importance of protecting investors from such detrimental financial impacts stemming from alleged misconduct.
Founded by Abraham L. Pomerantz, who is regarded as a pioneer in the field of class-action securities litigation, the firm has dedicated over eight decades to advocating for victims of securities fraud and misconduct. They’ve successfully recovered numerous multi-million dollar settlements for their clients, illustrating their commitment to holding corporations accountable.
For those looking to navigate these tumultuous waters of investment and litigation, the resources provided through Pomerantz LLP allow affected investors to make informed decisions about their next steps. By participating in this class action, investors may seek remediation for the losses they incurred as a result of the alleged malfeasance of Pacira’s leadership.
Investors are reminded that the deadline to become involved is fast approaching. It is pertinent to act swiftly to secure your place in this potentially significant case. By coming together, affected investors can amplify their influence in the quest for justice and recovery. Visit www.pomerantzlaw.com for additional details and to review the filed complaint.
In conclusion, with rising concerns surrounding corporate governance and transparency, cases like that of Pacira Biosciences spotlight the critical nature of investor vigilance in the face of potentially deceptive practices. It’s essential for shareholders to stay informed and proactive regarding their rights and the avenues available for pursuing compensation, especially during times of such significant corporate distress.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.